Lineage Cell Therapeutics Inc
F:BT3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lineage Cell Therapeutics Inc
F:BT3
|
US |
|
G
|
Grasim Industries Ltd
BSE:500300
|
IN |
|
B
|
Bank Central Asia Tbk PT
XMUN:BZG2
|
ID |
|
A
|
Akzo Nobel NV
LSE:0A00
|
NL |
|
H
|
Hackett Group Inc
F:AWT
|
US |
|
Netscout Systems Inc
NASDAQ:NTCT
|
US |
|
T
|
Tokyo Gas Co Ltd
DUS:TOG
|
JP |
|
S
|
Schlumberger NV
XMUN:SCL
|
US |
|
GitLab Inc
NASDAQ:GTLB
|
US |
|
M
|
Myriad Genetics Inc
SWB:MYD
|
US |
|
Yamana Gold Inc
TSX:YRI
|
CA |
|
U
|
Unisys Corp
SIX:UIS
|
US |
|
M
|
Myers Industries Inc
F:MJF
|
US |
|
Sitowise Group Oyj
F:1FT
|
FI |
|
GitLab Inc
F:8K2
|
US |
|
Nextera Energy Inc
NYSE:NEE
|
US |
|
Hong Kong and China Gas Co Ltd
OTC:HOKCF
|
HK |
|
Y
|
Yara International ASA
XMUN:IU2
|
NO |
|
Capital Clean Energy Carriers Corp
NASDAQ:CCEC
|
GR |
|
JSR Corp
TSE:4185
|
JP |
|
G
|
Greif Inc
F:GR3
|
US |
|
A
|
Adecoagro SA
F:ACD
|
LU |
Bankruptcy Probability
Lineage Cell Therapeutics Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Solvency Ratios
Solvency Ratios Comparison
Lineage Cell Therapeutics Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| US |
L
|
Lineage Cell Therapeutics Inc
TASE:LCTX
|
245.8m ILS |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
450.6B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
206.9B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
179.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
130.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
53.4B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
80B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Lineage Cell Therapeutics Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, Lineage Cell Therapeutics Inc has total debt of 15k USD. This includes both short-term (0 USD) and long-term (15k USD) debt.
You can find a full breakdown on its Balance Sheet.
